Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Primary Objective
To compare the efficacy of ALVR105 to placebo in the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ disease as determined by an independent, blinded Clinical Adjudication Committee (CAC) through Week 14
Details
Age
Adult
Type of Study
Prevention
Locations
University of Colorado Hospital
Principal Investigator
Jonathan Gutman, MD
Study ID
Protocol Number: 20-2670
More information available at ClinicalTrials.gov: NCT05305040
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers